Ardelyx, Inc.
NASDAQ:ARDX · NASDAQ Global Market
-$0.06 today
Vol 9.83M · Avg 3.58M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-36.9%
avg -63.2%
ROIC
-9.9%
avg -43.1%
ROA
-12.3%
avg -39.7%
Analysis
ROIC is currently the strongest return metric at -9.9% versus its period average of -43.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Michael G. Raab | President, Chief Executive Officer & Director | $1.43M | — | 61 | $1.74M | 0.70% |
Laura A. Williams | Chief Patient Officer & Interim Chief Medical Officer | $739,126.00 | — | 63 | $434,579.00 | 0.18% |
Rajani Dinavahi | Chief Medical Officer | $664,810.00 | — | — | $201,000.00 | 0.08% |
Mike Kelliher | Chief Business Officer | $622,498.00 | — | 49 | $361,766.00 | 0.15% |
John Bishop | Chief Technical & Quality Officer | $599,510.00 | — | 64 | $336,845.00 | 0.14% |
Sue Hohenleitner | Chief Financial Officer | $507,345.00 | — | 55 | $229,078.00 | 0.09% |
Eric Duane Foster | Chief Commercial Officer | — | — | 51 | $422,804.00 | 0.17% |
Caitlin Lowie | Vice President of Corporate Communications & Investor Relations | — | — | — | — | — |
Felecia W. Ettenberg | Chief Legal Officer | — | — | 55 | $237,000.00 | 0.10% |
James Brady | Chief Human Resources Officer | — | — | 55 | $261,066.00 | 0.11% |
Joseph Reilly | Senior Vice President of Finance & Principal Accounting Officer | — | — | 52 | $149,107.00 | 0.06% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$1.95M
Sells
63
$4.11M
Net Sentiment
$2.17M
Net selling
Most Active
RAAB MICHAEL
16 transactions
1–10 of 64
Analysis
Insiders reported 1 buys worth $1.95M and 63 sells worth $4.11M over the last 12 months. That adds up to net selling of $2.17M. RAAB MICHAEL was the most active insider with 16 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | -6.0% | +33.7% (14yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at -6.0% over three years. Forward estimates point to Revenue at +33.7% (14yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Spyre Therapeutics, Inc.
NASDAQ:SYRE
$5.31B
Trevi Therapeutics, Inc.
NASDAQ:TRVI
$2.39B
Pharvaris N.V.
NASDAQ:PHVS
$2.28B
BioCryst Pharmaceuticals, Inc.
NASDAQ:BCRX
$1.91B
Stoke Therapeutics, Inc.
NASDAQ:STOK
$1.87B
Intellia Therapeutics, Inc.
NASDAQ:NTLA
$1.69B
Zymeworks Inc.
NASDAQ:ZYME
$1.68B
Maze Therapeutics, Inc.
NASDAQ:MAZE
$1.39B
Wave Life Sciences Ltd.
NASDAQ:WVE
$1.17B
Upstream Bio, Inc.
NASDAQ:UPB
$337.95M
Who manages ARDX?
Ardelyx, Inc. (ARDX) lists 11 active executives. The top listed executive is Sue Hohenleitner, Chief Financial Officer.
Are ARDX insiders buying or selling?
Recent insider activity shows net buying of $25.74M.
Explore More
Continue the stock analysis
Jump to another research area for this company.